S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS

42Citations
Citations of this article
53Readers
Mendeley users who have this article in their library.

Abstract

Background: This study reports on clinical data from an 8-week open-label study of 20 HIV-seropositive individuals, diagnosed with Major Depressive Disorder (DSM-IV), who were treated with SAM-e (S-Adenosylmethionine). SAM-e may be a treatment alternative for the management of depression in a population reluctant to add another "pill" or another set of related side effects to an already complex highly active antiretroviral therapy (HAART) regimen. Methods: The Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression Inventory (BDI) were used to assess depressive symptomatology from 1,2,4,6 and 8 weeks after initiation of treatment with SAM-e. Results: Data show a significant acute reduction in depressive symptomatology, as measured by both the HAM-D and the BDI instruments. Conclusions: SAM-e has a rapid effect evident as soon as week 1 (p < .001), with progressive decreases in depression symptom rating scores throughout the 8 week study. © 2004 Shippy et al; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Shippy, R. A., Mendez, D., Jones, K., Cergnul, I., & Karpiak, S. E. (2004). S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS. BMC Psychiatry, 4. https://doi.org/10.1186/1471-244X-4-38

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free